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Limbic encephalitis is an inflammatory disease of the central nervous system characterized by diverse neurologic symptoms
including mnestic disturbances, hallucinations, and seizures as well as behavioral symptoms like depression, personality changes,
and acute confusional states resembling dementia. Several antibodies have been described in the pathogenesis of limbic encephalitis.
It is often a paraneoplastic syndrome associated with small cell lung cancer, breast cancer, or Hodgkin’s lymphoma among others.
Here, we report a patient with B-cell chronic lymphocytic leukemia (B-CLL), presenting with otherwise unexplained neurologic
symptoms consistent with limbic encephalitis. Despite intensive diagnostic procedures, no causing agent could be identified.
Pleocytosis consisting of T cells was detected in the cerebrospinal fluid (CSF). We initiated anti-B-cell therapy with Rituximab
for B-CLL with quick and durable resolution of symptoms. We speculate that disruption of interaction between autoreactive T and
malignant B cells is responsible for the therapeutic effect of Rituximab.
1. Case Presentation
A 77-year-old patient with B-cell chronic lymphocytic
leukemia was admitted to our hospital for evaluation of a
progressive deterioration of his general condition, ataxia, and
signs of a delirious syndrome in October 2007. The patient’s
wife had noticed personality changes and intermittent disori-
entation for approximately three weeks prior to admission.
The CLL had been diagnosed in 2001 and had shown an
indolent course. The leukemic cells were ZAP70 and CD38
negative. A biweekly low-dose therapy with chlorambucil
had been started in June 2007 when the leucocyte count
had reached 200.000/𝜇L. Hemoglobin value was 11.2 g/dL;
the platelet count was 226.000/𝜇L. With this therapy, the
leucocytes had slowly decreased to 106.000/𝜇L in September
2007, when the treatment was stopped. At the time of admis-
sion, there was no palpable lymphadenopathy or systemic
symptoms. The spleen was slightly enlarged; a moderate
hypogammaglobulinemia was present. The further medical
history included chronic obstructive pulmonary disease and
lumbar spinal stenosis. Seven years before the present admis-
sion, the patient had suffered a transient cerebral ischemia
without any residual neurological deficiency.
At initial evaluation, the patient showed mnestic distur-
bances and fluctuating disorientation with aphasic phases, as
well as severe ataxia. No focal abnormalities were found at
neurological examination. Cerebral computed tomography
(CT) scan and contrast magnetic resonance imaging (MRI)
showed no signs of acute cerebral ischemia, encephalitis,
or meningeal enhancement (Figure 1).The electroencephalo-
gram (EEG) was consistent with a general cerebral dys-
function, but without focal changes. Examination of the
CSF demonstrated a massive lymphocytic pleocytosis (768
cells/𝜇L) composed almost exclusively of CD3+ cells, and
elevated protein (130mg/dL), with no evidence of oligoclonal
bands but rather of intrathecal IgM synthesis. Unfortunately,
flow cytometric evaluation of CSF to further differentiate
T-cells was not performed. No infectious agents, especially
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Figure 1: Axial FLAIR images obtained before initiation of Rituximab. Normal anatomy and signal intensity of limbic system were seen at
initial presentation as well as after longer course of disease (left: November 2007; right: February 2008).
no herpes simplex virus, varicella zoster virus, Epstein-Barr
virus, cytomegalovirus, parvovirus, enterovirus, adenovirus,
toxoplasma, mycoplasma, borrelia, or lues, could be detected.
There were no atypical cells in repeated CSF analyses. The
serum tested negative for paraneoplastic antibodies against
Hu, Yo, Ri, Amphiphysin, CRMP5, Ma-1, Ma-2, CV2, and
voltage-gated potassium channels. A CT scan of the chest and
abdomen revealed ubiquitous slightly enlarged lymph nodes,
attributed to the CLL, but no signs of other malignancies.
Rehydration and empirical antibiotic therapy with
cefuroxime for a documented urinary tract infection showed
transient and modest improvement of the intermittent
confusion, but cognitive symptoms persisted. Neuro-
psychological examination revealed a dysexecutive syndrome
and an impaired short-term memory.
At this point, no definite diagnosis could be established.
Viral encephalitis (with unknown pathogen) was suspected
and no specific treatment was initiated. The patient was
admitted to a rehabilitation clinic for physiotherapeutic
treatment.
Within the following weeks, both the physical and the
mental condition of the patient further worsened, and he
developed a wasting-like syndrome with a weight loss of
approximately 20 kg within two months, with severe inappe-
tence, gait disturbances, and persisting cognitive dysfunction
resembling dementia.
Because of the progressive clinical symptoms in the
absence of any evidence for other diseases than the CLL and
the findings in the cerebrospinal fluid, a tentative diagnosis of
limbic encephalitis, possibly paraneoplastic, was established.
Due to the severely reduced performance status of the
patient rendering any intensive therapy impossible and con-
sidering its activity against both B-cell malignancies and
some autoimmune conditions, we initiated a weekly systemic
treatment with the monoclonal CD20 antibody, Rituximab.
After four times of systemic administration of Rituximab
(375mg/m2), we noticed a substantial improvement of the
neurologic symptoms and a decline in cells in the CSF, still
composed of CD3+ T cells (from initial 768/𝜇L to 300/𝜇L).
The peripheral lymphocyte count dropped to normal val-
ues. The total WBC was 3.500/𝜇L with >70% neutrophils;
hemoglobin and platelets were within normal limits.
Since then and without any further specific treatment,
the condition of the patient completely recovered. After more
than three years, there was no evidence of neurologic impair-
ment and the CLL was not detectable in peripheral blood.
The patient was in a very good condition and underwent
successful surgery for spinal stenosis. However, he deceased
due to postoperative complications unrelated to CLL or the
limbic encephalitis following surgical prostatectomy in a
community hospital.
2. Discussion
Cerebral or meningeal involvement is a very rare event in
patients with CLL. The most common clinical presentations
are confusional state, meningitis with cranial nerve abnor-
malities, optic neuropathy, and cerebellar signs [1]. Neither
of those was present in our patient.
Another rare brain dysfunction in CLL patients is
the occurrence of progressive multifocal leukoencephalitis
(PML) [2]. The frequency of this disease, which is due to
infection with the polyoma virus JC, is increasing because
of the wider use of effective immunosuppressants and par-
ticularly purine analogues. In our patient there was neither
evidence of leukemic cells in the CSF nor evidence of JC virus
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infection.TheMRI also lacked focal cerebral lesions typical in
PML.
Limbic encephalitis is characterized by rapid develop-
ment of irritability, depression, sleep disturbances, seizures,
hallucinations, and short-term memory loss. The clinical
manifestations of limbic encephalitis are diverse and patients
often present with a puzzling clinical picture. Delayed diag-
nosis is common.
Limbic encephalitis was first considered to be a disorder
that almost always occurs in association with malignancies,
but several cases unrelated to cancer have been described. Its
occurrence has been associated with antibodies against intra-
cellular neuronal antigens (e.g., Anti-Hu, Anti-Ma2, Anti-
Yo, and CV2/CRMP5) or against cell membrane antigens
(e.g., voltage-gated potassium channel, VGKC; N-methyl-D-
aspartate receptors, NMDAR) [3]. In approximately 40% of
patients, no antibodies can be detected, so their absence does
not preclude the diagnosis [4]. Importantly, this finding raises
the possibility that the disease might be mediated by cellular
immunity. Amixed cellular and humoral pathogeneticmech-
anism is not uncommon in autoimmune diseases.
Radiologic criteria of paraneoplastic limbic encephalitis
include MRI FLAIR or T2 uni- or bilateral temporal lobe
hyperintensities [4]. Imaging criteria are facultative and it
is not unusual that patients with a syndrome typical of
limbic encephalitis have normalMRI studies. Conversely, it is
possible that the clinical picture is atypical, but theMRI shows
bilateral medial temporal lobe abnormalities [5]. In our case,
MRI showed no specific signs of limbic encephalitis.
Paraneoplastic limbic encephalitis (PLE) is most fre-
quently associated with small cell lung cancer but has
also been described in patients with other solid tumors.
PLE linked to Hodgkin’s lymphoma with antibodies against
metabotropic glutamate receptor 5 (mGlu-R5) is termed
Ophelia Syndrome. Association with non-Hodgkin’s lym-
phoma is rare [6–8]. To our knowledge, no case of chronic
lymphocytic leukemia with PLE has been described so far.
One case of T-cell pleocytosis in the CSF in a patient with B-
CLL who suffered from progressive somnolence and blurred
vision has been reported [9]. According to the case report,
no MRI was performed neither had the autoantibodies been
tested.
Our patient improved markedly after the initiation of
treatment with Rituximab. In the light of the severe, quickly
progressive deterioration of the patient’s condition until initi-
ation of anti B cell-therapy, we strongly assume a therapeutic
effect of Rituximab rather than spontaneous improvement.
The mechanism of action remains debatable.
The use of Rituximab and the following CD20 depletion
may have altered the interaction between B and T cells.
Rituximab-induced elimination of circulating B cell results in
significant clinical improvement in rheumatoid arthritis [10].
In this disorder, B cells may function as antigen-presenting
cells and are important for T-cell activation. Although such a
role for B cells has been demonstrated neither in CLL nor in
paraneoplastic syndromes, it has been known for long time
that quantitative and qualitative abnormalities of T cells are
present in B-CLL [11]. Recently, a murine model suggesting a
crucial role of T cells in CLL has been reported [12].
It is possible that improvement of the encephalitis in
our patient is due to a disruption of the interplay between
neoplastic B cells and reactive T cells. Such a mechanism
has been assumed in some variants of PLE associated with
autoantibodies such as anti-VGKC or anti-NMDAR, where T
cells are considered to play a role in antibody induction.
In an uncontrolled trial, a total of nine patients with
paraneoplastic syndromes, including one patient with PLE,
were treated with Rituximab [13]. Three patients showed a
response to the treatment with improvements of neurological
syndromes. Two of them had a small cell lung cancer that
responded completely to the concurrent chemotherapy.
Although we cannot formally exclude the fact that our
patient suffered from unidentified viral encephalitis, the
clinical course with the rapid improvement of the neuro-
logical symptoms in conjunction with the near complete
remission of the CLL is highly suggestive of paraneoplastic
CLL-related limbic encephalitis. In our opinion, CLLmust be
included among the malignancies possibly related to limbic
encephalitis. Considering the older age of many CLL patients
this condition might be underdiagnosed, being possibly
confused with other common causes of brain dysfunction in
older patients, such as Alzheimer’s disease or dementia.
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